ARS Pharmaceuticals (SPRY) Debt Ratio (2020 - 2026)

ARS Pharmaceuticals (SPRY) reported Debt Ratio of 0.34 for Q1 2026, up 14.11% sequentially from 0.29 in Q4 2025.

ARS Pharmaceuticals (SPRY) Debt Ratio (2020 - 2026) Analysis & Trends

ARS Pharmaceuticals (SPRY) has 4 years of Debt Ratio data on file, last reported at 0.34 in Q1 2026.

For the quarter ending Q1 2026, Debt Ratio changed N/A year-over-year to 0.34; the trailing twelve-month figure through Mar 2026 stood at 0.34 (changed N/A YoY), and the FY2025 full-year result was 0.29, changed N/A from the prior year.
Debt Ratio improved to 0.34 in Q1 2026, from 0.29 in the prior quarter.
In the past five years, Debt Ratio ranged from a high of 0.34 in Q1 2026 to a low of 0.26 in Q3 2025.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	1.41
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	0.11
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	0.05
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	ARS Pharmaceuticals	595.78 Mn	394.81 Mn	-	0.34

Historic Data

Download Data

Date	Value
Mar 31, 2026	0.34
Dec 31, 2025	0.29
Sep 30, 2025	0.26
Dec 31, 2021	0.08
Mar 31, 2021	0.00
Dec 31, 2020	0.00